0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Detection Methods Gut & Microbiome Nanoplastics Policy & Risk Remediation Sign in to save

Bilosomes and Biloparticles for the Delivery of Lipophilic Drugs: A Preliminary Study

Antioxidants 2023 5 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 35 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Maddalena Sguizzato, Giuseppe Valacchi, Giuseppe Valacchi, Francesca Ferrara, Francesca Ferrara, Francesca Ferrara, Nada Baraldo, Giuseppe Valacchi, Agnese Bondi, Agnese Bondi, Annunziata Guarino, Markus Drechsler, Giuseppe Valacchi, Giuseppe Valacchi, Rita Cortesi

Summary

Researchers investigated bile acid-based vesicles (bilosomes) and nanoparticles (biloparticles) as delivery systems for lipophilic drugs, using ursodeoxycholic acid and sodium cholate to improve the aqueous solubility of poorly water-soluble compounds. The preliminary study characterised the physicochemical properties of these formulations and evaluated their potential as drug carriers.

Polymers
Models
Study Type In vitro

In this study, bile acid-based vesicles and nanoparticles (i.e., bilosomes and biloparticles) are studied to improve the water solubility of lipophilic drugs. Ursodeoxycholic acid, sodium cholate, sodium taurocholate and budesonide were used as bile acids and model drugs, respectively. Bilosomes and biloparticles were prepared following standard protocols with minor changes, after a preformulation study. The obtained systems showed good encapsulation efficiency and dimensional stability. Particularly, for biloparticles, the increase in encapsulation efficiency followed the order ursodeoxycholic acid < sodium cholate < sodium taurocholate. The in vitro release of budesonide from both bilosytems was performed by means of dialysis using either a nylon membrane or a portion of Wistar rat small intestine and two receiving solutions (i.e., simulated gastric and intestinal fluids). Both in gastric and intestinal fluid, budesonide was released from bilosystems more slowly than the reference solution, while biloparticles showed a significant improvement in the passage of budesonide into aqueous solution. Immunofluorescence experiments indicated that ursodeoxycholic acid bilosomes containing budesonide are effective in reducing the inflammatory response induced by glucose oxidase stimuli and counteract ox-inflammatory damage within intestinal cells.

Sign in to start a discussion.

Share this paper